Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc.
| Last: | $24.47 |
|---|---|
| Change Percent: | -0.33% |
| Open: | $25.41 |
| Close: | $24.55 |
| High: | $26.08 |
| Low: | $22.87 |
| Volume: | 863,547 |
| Last Trade Date Time: | 03/06/2026 12:46:01 pm |
| Market Cap: | $870,211,090 |
|---|---|
| Float: | 25,421,062 |
| Insiders Ownership: | 2.66% |
| Institutions: | 32 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://arrivent.com/¿. |
| Country: | US |
| City: | Newtown Square |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about ArriVent BioPharma Inc. (NASDAQ: AVBP).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
